Although Anti-PD-1 and HDACi are clinically effective in ALL (Bachy and Coiffier, 2013; Burke et al., 2014), there are relatively few studies testing this combination of the two drugs. This evidence concerns the gene PDCD1 and acute lymphoblastic leukemia.